Methylphenidate extended release - Purdue Pharma

Drug Profile

Methylphenidate extended release - Purdue Pharma

Alternative Names: Aptensio XR; Biphentin Capsules; Methylphenidate ER; Methylphenidate extended release; PRC-063

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Purdue Pharma
  • Developer Purdue Pharma; Rhodes Pharmaceuticals
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 29 May 2017 Purdue Pharma initiates enrolment in a phase III trial for Attention deficit hyperactivity disorder (In Children) in USA (NCT03172481)
  • 01 Jan 2017 Rhodes Pharmaceuticals in collaboration with Purdue Pharma completes a phase III trial in Attention deficit hyperactivity disorder (In adults) in USA (PO) (NCT02555150)
  • 01 Sep 2015 Rhodes Pharmaceuticals in collaboration with Purdue Pharma initiates a phase III trial in Attention deficit hyperactivity disorder (In adults) in USA (PO) (NCT02555150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top